NCT00576056View on ClinicalTrials.gov

Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

January 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

April 30, 2010

Conditions
Carcinoma, Hepatocellular
Interventions
DRUG

Sorafenib

Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.

DRUG

TACE

TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.

Trial Locations (1)

15232

University of Pittsburgh Cancer Institute, Pittsburgh

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

University of Pittsburgh

OTHER